Processa Pharmaceuticals director granted 33,500 RSUs

Processa Pharmaceuticals, Inc. director Justin W. Yorke received a grant of 33,500 Restricted Stock Units (RSUs) on July 26, 2026.

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. director Justin W. Yorke received a grant of 33,500 Restricted Stock Units (RSUs) on July 26, 2026. Each RSU represents a contingent right to one share of common stock and vested upon grant, with distribution deferred until the earlier of termination, six months after grant, a change of control, or death. Following this grant, he holds 38,749 RSUs, stock options for 12,000 shares at an exercise price of $4.96, and common stock totaling 353 shares directly plus additional indirect holdings, all reflecting a 1-for-25 reverse stock split effected on December 17, 2025.

Insider Trade Summary

Grant/Award: 33,500 shares

Grant/Award 5 txns

Insider Yorke Justin W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units F1, F3	33,500	$0.00	$0.00
holding	Stock Options (Right to Buy) F2, F3	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 38,749 contracts (Direct); Stock Options (Right to Buy) — 12,000 contracts (Direct); Common Stock — 353 shares (Direct); Common Stock — 1,250 shares (Indirect, By Richland Fund, LLC); Common Stock — 496 shares (Indirect, By Directed Trust Company FBO Justin Yorke IRA)

Footnotes (3)

1. F1. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
2. F2. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
3. F3. Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

Key Figures

RSUs granted: 33,500 RSUs RSU holdings after grant: 38,749 RSUs Option exercise price: $4.96 per share +5 more

8 metrics

RSUs granted 33,500 RSUs Grant of Restricted Stock Units to director on July 26, 2026

RSU holdings after grant 38,749 RSUs Total Restricted Stock Units held by Justin W. Yorke following the grant

Option exercise price $4.96 per share Exercise price of stock options covering 12,000 shares of common stock

Stock options underlying shares 12,000 shares Common shares underlying Stock Options (Right to Buy), held directly

Direct common shares 353 shares Directly owned Processa Pharmaceuticals common stock

Indirect shares via Richland Fund, LLC 1,250 shares Common stock held indirectly through Richland Fund, LLC

Indirect shares via IRA trust 496 shares Common stock held indirectly via Directed Trust Company FBO Justin Yorke IRA

Reverse stock split ratio 1-for-25 Reverse stock split effected on December 17, 2025, reflected in reported holdings

Key Terms

Restricted Stock Units, Stock Options (Right to Buy), 1-for-25 reverse stock split, change of control

4 terms

Restricted Stock Units financial

"Each Restricted Stock Unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Options (Right to Buy) financial

"Stock Options (Right to Buy) vest one-third on the first anniversary date"

1-for-25 reverse stock split financial

"Reflects the 1-for-25 reverse stock split effected by the Issuer"

change of control financial

"distributed until the earlier of termination; six month anniversary; change of control; or death"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Justin W. Yorke receive from Processa Pharmaceuticals (PCSA) in this Form 4?

Justin W. Yorke received a grant of 33,500 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Processa Pharmaceuticals common stock, and the RSUs vested immediately on the July 26, 2026 grant date.

When will the 33,500 RSUs granted to Justin W. Yorke by PCSA be distributed?

The 33,500 RSUs will be distributed at the earlier of termination, six months after the grant date, a change of control, or death. Although the RSUs vested upon grant, actual share delivery is deferred until one of these specified triggering events occurs.

What are Justin W. Yorke’s RSU and option holdings in PCSA after the reported transactions?

After the reported grant, Justin W. Yorke holds 38,749 RSUs and stock options covering 12,000 shares of Processa common stock at an exercise price of $4.96 per share. These positions reflect the company’s previously effected 1-for-25 reverse stock split.

How many shares of Processa Pharmaceuticals (PCSA) common stock does Justin W. Yorke hold directly and indirectly?

Justin W. Yorke holds 353 shares of Processa common stock directly. Indirectly, he holds 1,250 shares through Richland Fund, LLC and 496 shares through Directed Trust Company FBO Justin Yorke IRA, as reported in the Form 4 holdings section.

Were Justin W. Yorke’s PCSA transactions reported as made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the transactions were not affirmed as made under a Rule 10b5-1 trading plan. The document-level checkbox for transactions pursuant to a Rule 10b5-1 plan is not marked as true for this filing.

How do the stock options reported for Justin W. Yorke in PCSA vest over time?

The stock options for 12,000 shares at $4.96 vest one-third on the first anniversary of the grant date, with the remaining two-thirds vesting ratably over the following two years, according to the vesting footnote in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/28/2026 - 08:31 PM Accepted by SEC EDGAR 07/28/2026 - 08:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yorke Justin W

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								353	D
Common Stock								1,250	I	By Richland Fund, LLC
Common Stock								496	I	By Directed Trust Company FBO Justin Yorke IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	07/26/2026		A		33,500(1)		(1)	(1)	Common Stock	33,500	$0	38,749(3)	D
Stock Options (Right to Buy)	$4.96							(2)	(2)	Common Stock	12,000		12,000(3)	D

Explanation of Responses:

1. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

2. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.

3. Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

	/s/ Justin W. Yorke by John J. Wolfel, as Attorney-in-Fact	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)